Theravance Biopharma Inc (TBPH)

Theravance Biopharma Inc (TBPH) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Sep 25, 2026: market cap $884M; returns 1 week +0.1%, 1 year +23.5%.

Theravance Biopharma Inc. (TBPH) is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines for specialty respiratory and neurological diseases. The company's primary revenue driver is YUPELRI® (revefenacin), a once-daily, nebulized long-acting muscarinic antagonist (LAMA) bronchodilator approved in the U.S.

Groups TBPH belongs to

• Healthcare
• Biotechnology
• Biopharmaceutical
• Commercial Stage
• Commercial Stage Biotech
• Chronic Obstructive Pulmonary Disease (COPD)
• Pharmaceuticals
• Royalty Streams
• Clinical Stage Biopharma

TBPH financial model: income statement, cash flow and balance sheet